Hospital consumables are the next pricing question. Predictability is the better answer
Published · By Gaurav Phogat
On 12 October the Centre told the Supreme Court that hospital consumables are the next pricing concern after cancer drugs. In the same affidavit it said a simple percentage cap would not work for them. That second point is the most useful line in the whole debate, because it moves the conversation from margins to what patients actually feel: whether they can predict their bill.
What happened
After NPPA approved, in principle, a 30% trade margin cap on non-scheduled cancer drugs on 8 October, the Centre filed an affidavit in the Supreme Court. As reported by ETV Bharat, it named consumables as another area of concern, with margins of 100% to 1,000% or more.
New to the topic? Industry Watch: the themes so far sets out the reading order.
The affidavit also explained why consumables are harder to regulate. Their prices run from ₹1 to ₹350 or more, a uniform margin expressed as a share of MRP would not cover the cost of selling the cheapest items, and setting a fair margin would need extensive consultation. At the 12 October hearing the Court asked why relief should stop at cancer drugs. The matter is next listed for 27 October.
My take
The debate is framed as a margin question. For patients, it is a predictability question.
Nobody admitted for a knee replacement shops for gloves, cannulas, IV sets and drapes. They see dozens of small lines they did not choose, could not have priced in advance and cannot check afterwards. Even if every line is fairly priced, a total that arrives as a surprise feels unfair.
A cap, if one comes, fixes the price of each item. It does not fix the surprise. Predictable pricing fixes the experience and removes much of the complaint, and a hospital can start on it without waiting for any notification.
I made a similar argument about medicines in what the hospital medicine pricing debate misses: patients judge pricing by how well it is explained, not only by the number. The 2019 cancer drug margin cap and this month’s 30% cap show the same pattern. Regulation sets the ceiling. Trust is decided by what the patient understood before the bill arrived.
What most coverage missed
Consumables are hard to regulate because they are many, cheap and used in different quantities for every patient. The Centre’s own affidavit says as much. Those same three properties are what make an itemised bill confusing.
So the answer that works for the regulator and the patient is the same one: stop presenting consumables as separate surprises and price the episode instead. Packages already do this for many procedures, as I covered in package pricing vs itemised billing. The opportunity is to extend that logic. Include consumables in a stated episode price wherever the clinical pathway is predictable, and show them as a clearly labelled range with an upper limit where it is not.
What I would do
- List the 20 procedures that generate the most billing queries and check how many have an all-inclusive package that says which consumables it covers.
- Add a plain “what’s included” section to every procedure page and every estimate.
- Show consumables outside the package as a range with an upper limit, and name the two or three reasons the final figure can move. More on this in getting a hospital estimate before admission.
- Have the billing desk walk the family through the consumables section before discharge, not after they query it. Log the questions in the CRM so you can see which ones repeat.
- Publish a short patient guide on how to read a hospital bill and link it from the estimate.
What to watch
- The 27 October hearing, and whether the Court asks for a formal consultation on consumables.
- Whether any proposal uses price bands instead of one percentage, which the affidavit’s own reasoning points towards.
- The final list and notification for the 30% cancer drug cap.
Sources: ETV Bharat, 12 October 2026, ETV Bharat, 8 October 2026, Business Upturn, 14 October 2026. Figures as reported at the time of writing.
Sources and further reading
- reported by ETV Bharat (etvbharat.com)
- ETV Bharat, 8 October 2026 (etvbharat.com)
- Business Upturn, 14 October 2026 (businessupturn.com)
Questions people ask
Single-use or low-cost items used during treatment, such as syringes, cannulas, catheters, IV sets, gloves, dressings and surgical drapes. They are billed separately on most itemised hospital bills.
Most everyday consumables are not. Some devices, such as coronary stents and knee implants, have had price caps in the past, but the bulk of consumables sit outside ceiling-price control.
As reported on 12 October 2026, the Centre said margins of 100% to 1,000% or more are prevalent on hospital consumables, and that a uniform percentage-of-MRP margin would not work because their prices range from ₹1 to ₹350 or more.
A percentage of a ₹1 item may not cover the cost of stocking and dispensing it, while the same percentage on a costly item could still be high. The Centre said a workable margin needs wide consultation.
Ask for a written estimate that says what the package includes and gives an expected range, with an upper limit, for anything billed outside it.
The matter is listed for 27 October 2026.
Read my takes first in Google Search
